A Prospective, Multicentric, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog Glargine Plus Glulisine With Premixed Insulin in Adult Patients With Type 2 Diabetes Mellitus

Trial Profile

A Prospective, Multicentric, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog Glargine Plus Glulisine With Premixed Insulin in Adult Patients With Type 2 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
    • 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top